Breakthroughs in SARS-CoV-2-monoclonal antibodies development
In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and the disease which spread all over the world, was named COVID-19. This pandemic has neg...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
ResearchersLinks, Ltd
2021-02-01
|
| Series: | Novel Research in Microbiology Journal |
| Subjects: | |
| Online Access: | https://nrmj.journals.ekb.eg/article_149375_ca43e278ae9d981f574bef2edd5da549.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411760706027520 |
|---|---|
| author | Yusuf Muhammed Mkpouto Pius Bashiru Sani Bulus Timothy Jafar Usman Musa Garba |
| author_facet | Yusuf Muhammed Mkpouto Pius Bashiru Sani Bulus Timothy Jafar Usman Musa Garba |
| author_sort | Yusuf Muhammed |
| collection | DOAJ |
| description | In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in
China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and the disease which spread all over the world, was named COVID-19. This pandemic has negatively
affected quality of life and economy worldwide, thus motivating thoughtful search for treatment and prevention
strategies. Efforts have been made in drug repositioning and vaccine development as well as development of
monoclonal antibodies. Monoclonal antibodies provide a long-lasting protective immunity against the pathogens,
and have been at the forefront line in the therapy of some viral diseases. This study aimed to review the advances
in SARS-CoV-2 monoclonal antibodies (mAbs) development. Most of the developed SARS-CoV-2 monoclonal
antibodies including; B38, CR3022, 47D11, and H4, have targeted the spike protein of the virus to prevent its
interaction with the host cell ACE-2 receptor. However, others such as Tocilizumab prevent the inflammation
caused by the cytokine storm. |
| format | Article |
| id | doaj-art-6260e02d4c01449483db7d6994df3a8a |
| institution | Kabale University |
| issn | 2537-0286 2537-0294 |
| language | English |
| publishDate | 2021-02-01 |
| publisher | ResearchersLinks, Ltd |
| record_format | Article |
| series | Novel Research in Microbiology Journal |
| spelling | doaj-art-6260e02d4c01449483db7d6994df3a8a2025-08-20T03:34:41ZengResearchersLinks, LtdNovel Research in Microbiology Journal2537-02862537-02942021-02-01511063107610.21608/nrmj.2021.149375Breakthroughs in SARS-CoV-2-monoclonal antibodies developmentYusuf Muhammed0Mkpouto Pius1Bashiru Sani2Bulus Timothy3Jafar Usman4Musa Garba5Department of Biochemistry, Federal University Gusau, NigeriaDepartment of Medical Genetics, University of Cambridge, United KingdomDepartment of Microbiology, Federal University Lafia, NigeriaDepartment of Biochemistry, Kaduna State University, NigeriaDepartment of Biochemistry, Federal University Gusau, NigeriaFaculty of Pharmaceutical Sciences Kaduna State University, NigeriaIn December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), and the disease which spread all over the world, was named COVID-19. This pandemic has negatively affected quality of life and economy worldwide, thus motivating thoughtful search for treatment and prevention strategies. Efforts have been made in drug repositioning and vaccine development as well as development of monoclonal antibodies. Monoclonal antibodies provide a long-lasting protective immunity against the pathogens, and have been at the forefront line in the therapy of some viral diseases. This study aimed to review the advances in SARS-CoV-2 monoclonal antibodies (mAbs) development. Most of the developed SARS-CoV-2 monoclonal antibodies including; B38, CR3022, 47D11, and H4, have targeted the spike protein of the virus to prevent its interaction with the host cell ACE-2 receptor. However, others such as Tocilizumab prevent the inflammation caused by the cytokine storm.https://nrmj.journals.ekb.eg/article_149375_ca43e278ae9d981f574bef2edd5da549.pdfsars-cov-2spike proteinb cellst cellsmonoclonal antibodies |
| spellingShingle | Yusuf Muhammed Mkpouto Pius Bashiru Sani Bulus Timothy Jafar Usman Musa Garba Breakthroughs in SARS-CoV-2-monoclonal antibodies development Novel Research in Microbiology Journal sars-cov-2 spike protein b cells t cells monoclonal antibodies |
| title | Breakthroughs in SARS-CoV-2-monoclonal antibodies development |
| title_full | Breakthroughs in SARS-CoV-2-monoclonal antibodies development |
| title_fullStr | Breakthroughs in SARS-CoV-2-monoclonal antibodies development |
| title_full_unstemmed | Breakthroughs in SARS-CoV-2-monoclonal antibodies development |
| title_short | Breakthroughs in SARS-CoV-2-monoclonal antibodies development |
| title_sort | breakthroughs in sars cov 2 monoclonal antibodies development |
| topic | sars-cov-2 spike protein b cells t cells monoclonal antibodies |
| url | https://nrmj.journals.ekb.eg/article_149375_ca43e278ae9d981f574bef2edd5da549.pdf |
| work_keys_str_mv | AT yusufmuhammed breakthroughsinsarscov2monoclonalantibodiesdevelopment AT mkpoutopius breakthroughsinsarscov2monoclonalantibodiesdevelopment AT bashirusani breakthroughsinsarscov2monoclonalantibodiesdevelopment AT bulustimothy breakthroughsinsarscov2monoclonalantibodiesdevelopment AT jafarusman breakthroughsinsarscov2monoclonalantibodiesdevelopment AT musagarba breakthroughsinsarscov2monoclonalantibodiesdevelopment |